Business Context and Reporting Period
This Form 8-K Current Report was filed by Prime Medicine, Inc. on January 4, 2024. The report discloses the appointment of a new Chief Financial Officer and the transition of the interim CFO, effective January 17, 2024.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Base Salary: $500,000 annually for the new CFO.
- Sign-on Bonus: $176,000 one-time payment.
- Target Bonus: 40% of annual base salary.
- Equity Grants: 600,000 shares (time-based vesting) and 250,000 shares (milestone-based vesting).
Material Changes
The primary material change is the leadership transition in the finance department:
- Appointment: Allan Reine appointed as Chief Financial Officer and Principal Financial Officer.
- Transition: Carman Alenson transitions from Interim CFO to Senior Vice President, Finance and Chief Accounting Officer, stepping down as Principal Financial Officer.
Outlook, Risks, and Unusual Items
Management Commentary: Dr. Reine brings over 20 years of biotechnology experience, including prior CFO roles at Foghorn Therapeutics and Pieris Pharmaceuticals.
Compensation Contingencies:
- Termination without Cause/Good Reason: Entitles Dr. Reine to 9 months of base salary plus 0.75x target bonus, paid over 9 months, plus COBRA health coverage.
- Change in Control: If termination occurs within 12 months of a change in control, benefits increase to 12 months of base salary plus 1.0x target bonus, paid as a lump sum, with full acceleration of time-based equity awards.
Investor Verification Checklist
- Verify the effective date of the CFO transition (January 17, 2024).
- Confirm the vesting schedule details for the 600,000 time-based and 250,000 milestone-based stock options.
- Review the attached Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Monitor future filings for the impact of the new CFO on financial reporting and strategic direction.